Pyxis Oncology, Inc.
PYXS
$2.62
$0.020.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -79.62M | -97.09M | -96.29M | -95.23M | -77.33M |
| Total Depreciation and Amortization | 4.51M | 2.16M | 2.37M | 2.42M | 2.98M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.67M | 30.13M | 28.89M | 27.97M | 28.50M |
| Change in Net Operating Assets | 1.94M | -7.57M | -8.72M | 5.35M | -11.82M |
| Cash from Operations | -63.50M | -72.37M | -73.75M | -59.50M | -57.67M |
| Capital Expenditure | -9.00K | -9.00K | 0.00 | 0.00 | -237.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 58.87M | 69.26M | 57.77M | 42.47M | 8.39M |
| Cash from Investing | 58.86M | 69.25M | 57.77M | 42.47M | 8.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 742.00K | 2.00K | 1.66M | 1.81M | 59.52M |
| Repurchase of Common Stock | -148.00K | -7.73M | -7.72M | -7.70M | -7.89M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 7.70M | 7.70M | 7.70M | 7.70M |
| Cash from Financing | 594.00K | -25.00K | 1.64M | 1.82M | 59.33M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.05M | -3.14M | -14.34M | -15.21M | 9.81M |